To date, there have been no studies or reports suggesting patients with celiac disease are at increased risk of COViD-19 compared to patients without celiac disease. A small proportion of celiac disease patients with severe malnutrition and weight loss, the rare complication of Type 2 refractory celiac disease, on immunosuppressive medications or with other serious illnesses may be at increased risk and should consult with their physicians. Children and adults with celiac disease, like everyone in our communities, are at risk for COVID-19 infection and should exercise careful infection control practices: social distancing, frequent hand washing and avoiding touching their eyes, nose and mouth. —From the SSCD Executive Council
SSCD leaders and members networking to build a better society.
SSCD has worked to develop a statement regarding the use of oats in products that are identified as gluten-free
Read SSCD's statement on the use of low gluten wafers (pub.8/17)
Did you miss the September 22, 2021 webinar: Challenging Celiac Diagnosis When Patients are Already on a Gluten-Free Diet?
SSCD members can view the recording here.
Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease
Progress has been made in understanding coeliac disease, a relatively frequent and underappreciated immune- mediated condition that occurs in genetically predisposed individuals. However, several gaps remain in knowledge related to diagnosis and management. The gluten- free diet, currently the only available management, is not curative or universally effective (some adherent patients have ongoing duodenal injury). Unprecedented numbers of emerging therapies, including some with novel tolerogenic mechanisms, are currently being investigated in clinical trials. In March 2020, the Celiac Disease Foundation and the Society for the Study of Celiac Disease convened a consensus workshop to identify high- yield areas of research that should be prioritized. Workshop participants included leading experts in clinical practice, academia, government and pharmaceutical development, as well as representatives from patient support groups in North America. This Roadmap summarizes key advances in the field of coeliac disease and provides information on important discussions from the consensus approach to address gaps and opportunities related to the pathogenesis, diagnosis and management of coeliac disease. The morbidity of coeliac disease is often underestimated, which has led to an unmet need to improve the management of these patients. Expanded research funding is needed as coeliac disease is a potentially curable disease. Read the full article
FDA conference on celiac disease July 22
On Thursday, July 22 the United States Food and Drug Administration (FDA) will be hosting a day-long online public workshop on celiac disease, described as a forum for stakeholders to discuss trial elements to facilitate drug development. A brief summary of the meeting is below. Further details and registration for this free conference can be found here: https://www.eventbrite.com/e/great-vi-workshop-on-celiac-disease-tickets-145322155479
ABOUT THE PUBLIC WORKSHOP
FDA is announcing a public workshop for celiac disease. Discussions will focus on the approach to drug development in celiac disease and include the following topic areas:
• The histologic endpoints to assess treatment benefit in patients with celiac disease
• Regulatory framework for pediatric drug development in celiac disease
• The role of gluten challenge in clinical trials ICDS Sorrento Postponed to October 19-22, 2022
Following the discussion we had at the last Board meeting, considering the epidemiological uncertainties, the likely difficulties in travelling, the numerous requests received, after further considerations and contacts, the LOC has decided to postpone the Sorrento ICDS to October 19-22, 2022 to ensure the largest possible attendance in person. We invite the Presidents representing SSCD and ESSCD in the Board to inform the members of their Societies. At the next Board meeting we will discuss the impact this may have on the dates of the following ICDS.
It has been a very difficult decision, we hope for the benefit of our scientific community.
Thank you very much for your support.
For the LOC
Riccardo Troncone and Carolina Ciacci
SSCD Statement on Covid-19 Vaccination
With the recent news that the Food and Drug Administration has granted Emergency Use Authorization for a vaccine against SARS-CoV-2, the virus that causes Covid-19, patients with celiac disease are asking for guidance about the advisability of this and other Covid-19 vaccines in the context of celiac disease, an immune-mediated condition. As scientists and clinicians who care for people with celiac disease, we urge people with celiac disease to receive a Covid-19 vaccine that has met government regulatory approval. Click here to read more.
Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation
The advantage of a high-tryptophan diet
Although 40% of the worldwide population express celiac disease susceptibility genes, only 1% will develop the disorder, suggesting a role for environmental factors, including the gut microbiota. Lamas et al. show that celiac disease is associated with an impaired capacity of the gut microbiota to metabolize tryptophan into aryl hydrocarbon receptor (AhR) ligands in patients with celiac disease. Gluten-induced immunopathology in mice expressing a celiac disease susceptibility gene was ameliorated after AhR pathway activation by a high-tryptophan diet, or by treatment with a pharmacological AhR agonist or bacteria producing AhR ligands. AhR pathway modulation by the gut microbiota may have potential as a therapeutic strategy for treating celiac disease. Click here to read more.
Nanoparticles Show Promise as a Treatment for Celiac Disease
New study suggests gluten could be prevented from triggering the damaging immune reaction. A potential treatment for celiac disease in which nanoparticles act like a Trojan horse and carry a hidden component of gluten to reprogram the immune system not to react has shown positive early results in a new clinical trial. Click here for more.
Our members are keeping us in the loop
SSCD members continue to provide resources and information to help the GI community understand celiac disease. Visit our Educational Resources CD Management section for links to intersting content.
A new member benefit: Visit our Educational Resources page for a link to the WGO Ask a Librarian resource. SSCD and WGO have arranged to provide you with monthly alerts to relevent research via WGO's Ask a Librarian service. Monthly alerts will put the latest research at your fingertips.
The society you trust to deliver relevant, useful information about celiac disease has a new name to reflect our global membership - -Society for the Study of Celiac Disease.
SSCD Members Educate
SSCD members shared their knowledge at a joint (NA)SSCD-CAG session. Read the commentary to learn more.
SSCD publishes guideline for Celiac Disease Diagnosis in Adults. Read it, share it, use it. A recent directive by the Vatican generated discussion about the use of low-gluten communion hosts as part of the Catholic mass. Read SSCD's statement on the issue.
Read our latest commentary on the inclusion of oats in a gluten-free diet on our news page.
Speaking of oats: Venessa Wong, business writer for BuzzFeed referenced the SSCD oats statement in her latest article on mechanically/optically sorted oats.
Attention members: To access members-only sections of the website, please login. If you do not recall your login credentials, please use the 'forgot password' function or contact Bina Mesheimer at 630-522-7886.